IN VIVO TESTING OF A LEAD COQ10 BIOSYNTHESIS INHIBITOR IN AN SK-BR-3 XENOGRAPH MOUSE MODEL

点击翻译按钮获取中文摘要

NCATS TDB has been collaborating with Dr Brent Stockwell’s group at Columbia Univ. to develop small molecules inhibitors of CoQ10 biosynthesis for the treatment of cancer. Currently, we have a series of inhibitors that show good potency and selectivity in vitro. We would like to test our lead inhibitor in a mouse model xenografted with SK-BR-3 human breast cancer cells. NCATS does not have in vivo efficacy testing facility nor capacity to run in vivo efficacy models, and therefore must get this service through a contractor.